Alzheimer’s Disease CE Course Preview

Accreditation Information

Course Title: Neurocognitive Disorder – Alzheimer’s Disease

Release date: July, 2020

Expiration date: July, 2022

Estimated time to complete activity: 1 hour

Hardware / Software Requirements: Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

If you have any questions, please contact MER at (800)-421-3756,

To see MER Privacy Policy, scroll to bottom of this page.

This activity is jointly provided by Medical Education Resources and Symptom Media.

Target Audience

Psychiatrist, psychologists, social workers, marriage and family therapists, substance abuse counselors, allied health professionals, nurses, general practice physicians, and students, interns, and trainees of these disciplines.

Underlying Need for this Course

The purpose of this activity is to expand the student’s overall knowledge about neurocognitive disorders and its differential diagnoses, with a special attention to the Alzheimer’s disease.

  1. The various types of degenerative disorders are often mixed up, due to all types of dementia sharing some commonalities.
  2. Differential diagnosis among different types of neurocognitive disorders can be quite challenging.

There is an estimate of 5.8 million Americans living with Alzheimer’s disease. This number is predicted to raise to 14 million in 30 years. It is the 6th leading cause of death in USA.  Early diagnosis can help but only 16% of seniors receive regular screening for cognitive deficits (Alzheimer’s Association, 2019).

Alzheimer’s disease confers 60-80% of all cases of dementia (APA, 2015). The challenge to diagnose this disorder lies on the fact that the symptoms may mimic those of other neurodegenerative disorders. There is not one single test or exam on a living individual that can accurately diagnosis Alzheimer’s, it may require a combination of tests and observed symptoms to close the diagnosis.

Alzheimer’s displaying symptoms are mostly common among other neurodegenerative disorders, but there will be particularities that show strong indication of Alzheimer’s disease.

Learning Objectives

By the end of this course learners will be able to:

  1. Define neurodegenerative disorders
  2. Identify the Alzheimer’s type of neurocognitive disorders
  3. Establish therapeutic milieu when treating patients with neurodegenerative disorders
  4. Identify treatment options that could delay the progress of the illness,  improve symptoms, assist in preserving functional level

Meet your instructor: Karen B. Silva PhD, MSFN, RN-BC. Board certified nurse in Mental Health and Psychiatric nursing. Has a doctoral degree in general psychology, and two master’s degrees in Advance practice Nursing in Adult and Geriatric Health and Forensic Nursing. Over 30 years of experience in psychiatric nursing  and over 12 years in education. Currently work as an Education Program Coordinator and Instructor of Psychiatry in a large hospital in Los Angeles, CA.

Course Agenda

The content of the lecture is focused on Alzheimer’s Disease. How it is presented in clinical settings, what to look for when diagnosing it, and what options are available to manage it.

The written content provides the learner with an overview of neurodegenerative disorders with focus in Alzheimer’s disease: definition, symptoms, diagnostic criteria per DSM-V, statistics, management of symptoms, prognosis, and differential diagnosis. It is followed by the video of an actress portraying the role of a patient with Alzheimer’s type dementia in advanced stage of the disease. The student will be able to see the severe cognitive impairment expected towards the advanced stage of Alzheimer’s disease.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Symptom Media. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1 contact hour.

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Method of Participation
There are no fees for participating in and receiving credit for this activity (or insert fee amount if applicable). During the period July, 2020 through July, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, 4) complete the evaluation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.


  • Alzheimer’s Association (2019). “Facts and Figures [Online].  Available at
  • Alzheimer’s Association. (2018). “Management” [Online]. Available at
  • Alzheimer’s Association. (2018). “Stages of Alzheimer’s” [Online]. Available at
  • American Psychiatric Association. (2013). Neurocognitive Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.). Available at
  • Dearing, T. (2016). Why letting dementia go undiagnosed can be a big mistake. NJ Advance Media. Available at
  • Edwards Iii, G. A., Gamez, N., Escobedo, G., Jr, Calderon, O., & Moreno-Gonzalez, I. (2019).  Modifiable Risk Factors for Alzheimer’s Disease. Frontiers in Aging Neuroscience, 11, 146. doi:10.3389/fnagi.2019.00146
  • Klatka L. A., Schiffer R. B., Powers J. M. and Kazee A. M. (1996) Incorrect diagnosis of Alzheimer’s disease. A clinicopathologic study. Archives of Neurology,  53, 35– 42.
  • Narashi, T.; Marszales, W.; Moriguchi, S.; Yeh, J. Z.; Zhao, X. (2003).  Unique mechanism of action of Alzheimer’s drugs on brain nicotinic acetylcholine receptors and NMDA receptors.  Life Sciences, 74(2-3), 281-291. Elsevier.
  • National Institute on Aging (December, 2017). What Is Dementia? Symptoms, Types, and Diagnosis. National Institute of Health.  Available at
  • Profenno, L.A.; Porsteinsson. A. P.; Faraone, S.V. (2010). Meta-Analysis of Alzheimer’s Disease Risk with Obesity, Diabetes, and Related Disorders. Biological Psychiatry, 67 (6), 505-512.


The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Symptom Media and/or [insert grantor]. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

MER Privacy Policy: